In this newsletter, we are pleased to provide an update on the innovative work taking place at the CGT Catapult development centre based in Guy's Hospital, London.
Targeting solid tumours - In a project targeting tumour vascular with CAR T-cells for the treatment of solid tumours, the industrialisation team has seen ~50% reduction in tumour burden using CAR-T cells targeted to CLEC14A. This data was presented at the recent American Society of Gene & Cell Therapy Annual Meeting and the British Society for Gene and Cell Therapy Annual Conference, where Analytical Development Scientist, Juan Miguel Sanchez-Nieto, won the oral presentation prize. You can see a copy of the presentation on our website.
Lowering viral vector manufacturing cost - In the area of viral vector manufacturing the team have investigated transduction as a major cost driver in the cost of viral vector and in CAR T-cell manufacturing. The team have shown that high cell seeding densities and lower working volumes, with little to no agitation, allowed the maximum transduction of T-cells. Through this bioprocess optimisation the virus cost per transduced cell was dramatically lowered. Data can be seen in this poster also presented at the American Society of Gene & Cell Therapy Annual Meeting.